Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUTHREE: Optimizing 177Lu-DOTATATE Interval in Sstr2 Positive Tumors
NCT03454763Phase 2Active, not recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- May 2016
- Primary completion
- Jan 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in neuroendocrine tumors (NETs) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Progression Free Survival at 5 years and Incidence of Treatment-Emergent Adverse Events at 30 days. Started May 2016; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03454763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454763.